Taking post #6 at face value and following it one step further. The pentadecapeptide sequence is short and stable enough to survive conditions that would degrade a larger peptide, which is one of the few things about it that is well characterised.
On the subject in the title: BPC-157: what the rodent literature actually shows, and what it does not — a second dataset Working notes rather than a conclusion.
The question about BPC-157 that I actually want answered is the second one below. The first is context and I have kept it short.
Both are stated with units, and I have said what I already checked so that nobody repeats it.
Two claims get bundled together under BPC-157 and they need separating. The descriptive one — this is what was observed — is usually well supported. The causal one — this is why — usually is not.
Almost every disagreement in threads like this one dissolves once you say which of the two you are making.
Adding the measurement that post #2 says would settle it.
Dose-response is unstudied in humans for essentially everything in this family, which means the confident numbers in circulation came from somewhere other than a trial.
It is the kind of thing that is obvious once and never again.
A note on scope: what I am saying about BPC-157 applies to the case in the first post and I would not extend it further without checking.
Reported local reactions are common enough in first-hand accounts here to be worth mentioning and are not characterised in any published series.
That is what the documentation says. What happens in practice is usually close.
Answering the question post #4 raises rather than the one it answers.
Reading a preclinical wound-healing model: the model shows whether a mechanism is plausible in a specific context. It does not show magnitude of effect in humans, does not show safety profile in humans, and does not show whether the effect survives in a more complex biological system. That is not a criticism of preclinical work — it is what preclinical work is for.
That is the honest state of it as of this week.
Taking post #6 at face value and following it one step further.
The pentadecapeptide sequence is short and stable enough to survive conditions that would degrade a larger peptide, which is one of the few things about it that is well characterised.
TB-500 is usually the 7-residue actin-binding fragment of thymosin beta-4, not the full 43-residue protein. The two are routinely conflated in supplier documentation and in the literature. Evidence about the full protein does not automatically apply to the fragment.
I would be glad to be shown a cleaner way of putting this.
I would keep BPC-157 and the decision it usually gets used for separate in this thread. They are related and they are not the same question, and merging them is why the last one went badly.
Everything in post #11 holds. The case it does not cover is the one I have.
The lyophilised cake is worth looking at before adding diluent. A collapsed or shrunken cake is not a purity finding but it does say something about how the vial was made and how it travelled.
I have changed my mind on this once already, so take it as current rather than settled.
Narrowing post #11, because the general version has more than one answer.
On BPC-157 the community has more anecdote than the confidence in this thread implies, and I include my own contribution in that.
Oral versus injected administration claims for BPC-157: the preclinical work studied injection. Oral claims are common in supplier marketing and poorly supported by published evidence. If you are comparing orality between compounds, that is a distinction worth noting.
Taking post #15 at face value and following it one step further.
Stability of BPC-157 in solution: what has been measured in published work covers specific formulations under specific conditions. Extrapolating to a reconstituted preparation in a different diluent at a different concentration is an extrapolation, acknowledged as one.
If it helps: the failure mode here is usually boring rather than dramatic.
I read post #15 twice before replying, because I had assumed the opposite.
BPC-157: I have looked for the primary source twice and failed twice. Either it does not exist or it is somewhere I do not know to look, and I would like to know which.
Nothing in this subcategory is medical advice and several members here are describing experiments on themselves. Both of those things should be stated plainly rather than implied.
That is what I would do. It may not be what is correct.
Same experience here, different supplier, so it is at least not unique to one of them.
Dose-response is unstudied in humans for essentially everything in this family, which means the confident numbers in circulation came from somewhere other than a trial.
It is one reading of the data and not the only reasonable one.
Something worth flagging about BPC-157: the strongest-sounding claims in this thread are the ones with no source attached, which is the usual pattern and not a coincidence.
Reframing BPC-157 slightly, because I think the disagreement is about the question rather than the answer. If the question is "does it happen", yes. If it is "how often", nobody here knows.
Confirming post #20 from a second method, which matters more than confirming it from a second person.
The absence of adequately powered published randomised human trials is the central fact about BPC-157. This site states that plainly rather than hedging. Mechanistic plausibility does not substitute for it.
Posted with less confidence than the sentence structure implies.
I had written a reply contradicting post #22 and deleted it. Here is what survived.
Publication patterns in the BPC-157 literature: a large proportion of the evidence comes from one research group. That is not necessarily wrong — one group can do excellent work — but it is worth noting when evaluating the breadth of support for a claim.
The short version is the first sentence; the rest is why.
Analytical identity of BPC-157: a 15-residue peptide with an unambiguous mass (≈1419.5 Da). Identity confirmation by LC-MS is trivially easy, which means there is no excuse for an unverified identity on this compound.
This is the sort of thing that ought to be settled and apparently is not.
The distinction between "no evidence it works" and "evidence it does not work": we have the first for these compounds. That is genuinely different from the second and the distinction matters, but it also means treatment plans based on these compounds are being built on theoretical grounds, not empirical ones.
This is the first time the answer has come with its own limits attached. Appreciated.
The arithmetic in post #27 is right; the assumption feeding it is the part to check.
BPC-157's published evidence is overwhelmingly preclinical and mostly rodent. That is not a dismissal — it is the state of the literature, and any discussion that starts elsewhere is starting from something that is not there.
Answering the question post #26 raises rather than the one it answers.
The preclinical work is genuinely interesting and it is preclinical. A rodent tendon model is a model of a rodent tendon, and the translation record from that kind of model is poor.
That is the practical version. The rigorous version is longer and says the same thing.